Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Venous Thromboembolism | 33 | 2024 | 1881 | 3.800 |
Why?
|
Pulmonary Embolism | 39 | 2024 | 2587 | 3.550 |
Why?
|
Anticoagulants | 36 | 2023 | 4842 | 1.800 |
Why?
|
Venous Thrombosis | 12 | 2024 | 1317 | 1.650 |
Why?
|
Blood Coagulation | 8 | 2020 | 1161 | 1.250 |
Why?
|
Warfarin | 6 | 2023 | 1493 | 1.250 |
Why?
|
Thrombosis | 8 | 2023 | 2955 | 1.200 |
Why?
|
Heparin | 10 | 2022 | 1636 | 1.160 |
Why?
|
Patient Care Team | 9 | 2020 | 2529 | 1.110 |
Why?
|
Hemorrhage | 22 | 2023 | 3461 | 1.010 |
Why?
|
Thrombolytic Therapy | 10 | 2024 | 2050 | 0.760 |
Why?
|
Thrombophilia | 2 | 2021 | 306 | 0.750 |
Why?
|
Administration, Oral | 12 | 2023 | 4043 | 0.720 |
Why?
|
African Swine Fever | 1 | 2020 | 7 | 0.700 |
Why?
|
Blood Coagulation Factors | 4 | 2020 | 366 | 0.670 |
Why?
|
Fibrin Fibrinogen Degradation Products | 5 | 2021 | 425 | 0.640 |
Why?
|
Heparin, Low-Molecular-Weight | 5 | 2023 | 344 | 0.610 |
Why?
|
Antithrombins | 1 | 2021 | 294 | 0.600 |
Why?
|
Aftercare | 2 | 2020 | 920 | 0.550 |
Why?
|
Neoplasms | 19 | 2024 | 22389 | 0.500 |
Why?
|
Pyridones | 2 | 2020 | 818 | 0.490 |
Why?
|
Standard of Care | 1 | 2018 | 570 | 0.450 |
Why?
|
Blood Coagulation Disorders | 3 | 2021 | 350 | 0.430 |
Why?
|
Flank Pain | 1 | 2013 | 44 | 0.430 |
Why?
|
Renal Veins | 1 | 2013 | 103 | 0.420 |
Why?
|
Pyrazoles | 3 | 2020 | 2021 | 0.400 |
Why?
|
Extracorporeal Membrane Oxygenation | 2 | 2020 | 1482 | 0.390 |
Why?
|
Obesity, Morbid | 1 | 2023 | 1306 | 0.390 |
Why?
|
Emergency Service, Hospital | 7 | 2024 | 7955 | 0.350 |
Why?
|
Partial Thromboplastin Time | 2 | 2021 | 204 | 0.330 |
Why?
|
Patient Compliance | 1 | 2020 | 2693 | 0.330 |
Why?
|
Hospitalization | 6 | 2024 | 10844 | 0.320 |
Why?
|
Anxiety | 1 | 2024 | 4675 | 0.320 |
Why?
|
Humans | 105 | 2024 | 768298 | 0.320 |
Why?
|
Coronavirus Infections | 3 | 2020 | 3118 | 0.310 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 3241 | 0.300 |
Why?
|
Practice Guidelines as Topic | 7 | 2021 | 7453 | 0.300 |
Why?
|
Peptide Fragments | 1 | 2020 | 5151 | 0.290 |
Why?
|
Thromboembolism | 3 | 2021 | 1004 | 0.290 |
Why?
|
Consensus | 5 | 2024 | 3212 | 0.290 |
Why?
|
Catheterization | 2 | 2020 | 1431 | 0.280 |
Why?
|
Factor VIIa | 1 | 2008 | 103 | 0.280 |
Why?
|
Hospital Rapid Response Team | 2 | 2018 | 54 | 0.280 |
Why?
|
Retrospective Studies | 22 | 2024 | 81768 | 0.260 |
Why?
|
Clinical Protocols | 4 | 2020 | 1445 | 0.260 |
Why?
|
Myeloproliferative Disorders | 2 | 2022 | 614 | 0.250 |
Why?
|
Middle Aged | 44 | 2024 | 223463 | 0.250 |
Why?
|
Risk Factors | 27 | 2024 | 74954 | 0.250 |
Why?
|
Critical Illness | 5 | 2021 | 2755 | 0.250 |
Why?
|
Stress, Physiological | 1 | 2012 | 1410 | 0.240 |
Why?
|
Pulmonary Artery | 3 | 2021 | 1945 | 0.240 |
Why?
|
Delivery of Health Care | 4 | 2024 | 5375 | 0.240 |
Why?
|
Female | 58 | 2024 | 397050 | 0.230 |
Why?
|
Depression | 1 | 2024 | 8241 | 0.230 |
Why?
|
Aged | 36 | 2024 | 171544 | 0.230 |
Why?
|
C-Reactive Protein | 4 | 2024 | 3859 | 0.220 |
Why?
|
Hematopoietic Cell Growth Factors | 2 | 2022 | 98 | 0.220 |
Why?
|
Male | 49 | 2024 | 364870 | 0.210 |
Why?
|
Acute Disease | 9 | 2024 | 7242 | 0.190 |
Why?
|
Risk Assessment | 13 | 2024 | 24316 | 0.180 |
Why?
|
Micropore Filters | 1 | 2020 | 22 | 0.180 |
Why?
|
Platelet Count | 2 | 2020 | 784 | 0.180 |
Why?
|
Ceruloplasmin | 1 | 2020 | 57 | 0.180 |
Why?
|
Iron Metabolism Disorders | 1 | 2020 | 24 | 0.180 |
Why?
|
Hypereosinophilic Syndrome | 1 | 2021 | 97 | 0.180 |
Why?
|
Thrombocytopenia | 4 | 2020 | 1180 | 0.180 |
Why?
|
Evidence-Based Medicine | 2 | 2010 | 3707 | 0.180 |
Why?
|
Pipecolic Acids | 1 | 2021 | 77 | 0.180 |
Why?
|
Drug Antagonism | 1 | 2019 | 50 | 0.170 |
Why?
|
Prothrombin | 1 | 2020 | 193 | 0.170 |
Why?
|
Hirudins | 1 | 2021 | 179 | 0.170 |
Why?
|
Endothelial Cells | 1 | 2012 | 3587 | 0.170 |
Why?
|
Adult | 30 | 2024 | 223622 | 0.170 |
Why?
|
Biomarkers, Pharmacological | 1 | 2020 | 162 | 0.170 |
Why?
|
von Willebrand Disease, Type 1 | 1 | 2019 | 5 | 0.160 |
Why?
|
Fibrinolytic Agents | 4 | 2023 | 2073 | 0.160 |
Why?
|
Probability | 1 | 2024 | 2482 | 0.160 |
Why?
|
Deamino Arginine Vasopressin | 1 | 2019 | 87 | 0.160 |
Why?
|
Biological Specimen Banks | 1 | 2024 | 782 | 0.160 |
Why?
|
Recombinant Proteins | 3 | 2021 | 6512 | 0.150 |
Why?
|
Ultrasonography, Doppler | 1 | 2020 | 463 | 0.150 |
Why?
|
Outpatients | 4 | 2018 | 1603 | 0.150 |
Why?
|
Drug Monitoring | 2 | 2021 | 964 | 0.150 |
Why?
|
Ambulatory Care | 2 | 2020 | 2784 | 0.150 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 250 | 0.140 |
Why?
|
Pyrrolidinones | 1 | 2018 | 116 | 0.140 |
Why?
|
Risk Adjustment | 1 | 2021 | 603 | 0.140 |
Why?
|
Thrombectomy | 3 | 2017 | 671 | 0.140 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 11854 | 0.140 |
Why?
|
Hemoglobinuria, Paroxysmal | 1 | 2017 | 96 | 0.140 |
Why?
|
Hospitals, University | 1 | 2019 | 568 | 0.140 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2021 | 12239 | 0.140 |
Why?
|
Dextrocardia | 1 | 2016 | 37 | 0.140 |
Why?
|
Emergency Treatment | 2 | 2018 | 496 | 0.140 |
Why?
|
Antiphospholipid Syndrome | 1 | 2018 | 166 | 0.140 |
Why?
|
Treatment Outcome | 14 | 2024 | 65365 | 0.130 |
Why?
|
Anemia | 3 | 2022 | 1520 | 0.130 |
Why?
|
Multiple Myeloma | 2 | 2023 | 5192 | 0.130 |
Why?
|
Amygdala | 1 | 2024 | 1382 | 0.130 |
Why?
|
Plasma | 1 | 2019 | 585 | 0.130 |
Why?
|
Heart Rate | 2 | 2024 | 4218 | 0.130 |
Why?
|
Purpura, Thrombocytopenic, Idiopathic | 1 | 2020 | 246 | 0.130 |
Why?
|
Tissue Plasminogen Activator | 1 | 2021 | 1163 | 0.120 |
Why?
|
Decision Support Systems, Clinical | 1 | 2024 | 1177 | 0.120 |
Why?
|
History, 19th Century | 1 | 2017 | 715 | 0.120 |
Why?
|
Leukemia | 1 | 2022 | 1526 | 0.110 |
Why?
|
Patient Transfer | 1 | 2021 | 793 | 0.110 |
Why?
|
Ultrasonography | 2 | 2020 | 6001 | 0.110 |
Why?
|
Mass Screening | 1 | 2010 | 5451 | 0.110 |
Why?
|
China | 1 | 2020 | 2389 | 0.110 |
Why?
|
Incidence | 3 | 2024 | 21544 | 0.110 |
Why?
|
Cardiovascular Diseases | 3 | 2024 | 15652 | 0.110 |
Why?
|
Aorta | 1 | 2021 | 2046 | 0.110 |
Why?
|
Drug Administration Schedule | 2 | 2019 | 4859 | 0.100 |
Why?
|
Aged, 80 and over | 10 | 2024 | 59683 | 0.100 |
Why?
|
Drug Interactions | 1 | 2017 | 1420 | 0.100 |
Why?
|
Hospital Mortality | 2 | 2024 | 5367 | 0.100 |
Why?
|
Artificial Intelligence | 2 | 2024 | 2661 | 0.100 |
Why?
|
ROC Curve | 1 | 2020 | 3622 | 0.100 |
Why?
|
Echocardiography | 3 | 2020 | 5044 | 0.100 |
Why?
|
Quinolines | 1 | 2018 | 768 | 0.100 |
Why?
|
Lower Extremity | 1 | 2020 | 1218 | 0.100 |
Why?
|
Obesity | 3 | 2023 | 13082 | 0.100 |
Why?
|
Antibodies, Antinuclear | 1 | 2013 | 343 | 0.100 |
Why?
|
Emergency Medicine | 2 | 2019 | 1222 | 0.100 |
Why?
|
Anemia, Hemolytic, Autoimmune | 1 | 2013 | 147 | 0.100 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2018 | 5422 | 0.100 |
Why?
|
Cross Infection | 1 | 2021 | 1422 | 0.100 |
Why?
|
Medical Oncology | 2 | 2020 | 2348 | 0.100 |
Why?
|
Hypertension, Pulmonary | 1 | 2022 | 1597 | 0.090 |
Why?
|
Point-of-Care Systems | 1 | 2020 | 1238 | 0.090 |
Why?
|
Neurodegenerative Diseases | 1 | 2020 | 1094 | 0.090 |
Why?
|
History, 21st Century | 1 | 2017 | 1575 | 0.090 |
Why?
|
Thromboplastin | 1 | 2012 | 288 | 0.090 |
Why?
|
Ventricular Dysfunction, Right | 1 | 2016 | 644 | 0.090 |
Why?
|
Intensive Care Units | 3 | 2021 | 3800 | 0.090 |
Why?
|
Hypotension | 1 | 2016 | 889 | 0.090 |
Why?
|
Inpatients | 2 | 2021 | 2569 | 0.090 |
Why?
|
Pandemics | 5 | 2021 | 8750 | 0.090 |
Why?
|
Disease Outbreaks | 1 | 2020 | 1762 | 0.090 |
Why?
|
Enoxaparin | 1 | 2012 | 391 | 0.090 |
Why?
|
Occupational Exposure | 1 | 2020 | 1817 | 0.080 |
Why?
|
Patient Readmission | 1 | 2024 | 3312 | 0.080 |
Why?
|
Swine | 1 | 2020 | 5993 | 0.080 |
Why?
|
Hematologic Neoplasms | 1 | 2021 | 1906 | 0.080 |
Why?
|
Headache | 1 | 2017 | 1262 | 0.080 |
Why?
|
Massachusetts | 2 | 2020 | 8902 | 0.080 |
Why?
|
Factor Xa | 2 | 2020 | 166 | 0.080 |
Why?
|
History, 20th Century | 1 | 2017 | 2771 | 0.080 |
Why?
|
Vena Cava Filters | 3 | 2017 | 270 | 0.080 |
Why?
|
Heart Ventricles | 1 | 2021 | 3838 | 0.080 |
Why?
|
Review Literature as Topic | 2 | 2008 | 353 | 0.080 |
Why?
|
Stress, Psychological | 1 | 2024 | 4543 | 0.080 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2023 | 3252 | 0.080 |
Why?
|
Heart Failure | 2 | 2022 | 11860 | 0.070 |
Why?
|
Cohort Studies | 8 | 2024 | 41791 | 0.070 |
Why?
|
Kidney Diseases | 1 | 2018 | 2103 | 0.070 |
Why?
|
Thalidomide | 1 | 2012 | 886 | 0.070 |
Why?
|
Referral and Consultation | 1 | 2020 | 3627 | 0.070 |
Why?
|
Health Personnel | 1 | 2020 | 3381 | 0.070 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2024 | 4637 | 0.070 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2014 | 1614 | 0.070 |
Why?
|
Lung Neoplasms | 3 | 2018 | 13576 | 0.060 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2020 | 3440 | 0.060 |
Why?
|
Quality of Life | 2 | 2024 | 13499 | 0.060 |
Why?
|
Antineoplastic Agents | 2 | 2022 | 13696 | 0.060 |
Why?
|
Cluster Analysis | 1 | 2012 | 2727 | 0.060 |
Why?
|
Shock | 1 | 2008 | 316 | 0.060 |
Why?
|
Resource Allocation | 1 | 2008 | 354 | 0.060 |
Why?
|
Diagnosis, Differential | 3 | 2020 | 13019 | 0.060 |
Why?
|
Dexamethasone | 1 | 2012 | 1965 | 0.060 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 14736 | 0.060 |
Why?
|
Longitudinal Studies | 2 | 2019 | 14783 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2023 | 9433 | 0.060 |
Why?
|
Recurrence | 3 | 2023 | 8501 | 0.060 |
Why?
|
Atrial Fibrillation | 1 | 2022 | 5168 | 0.060 |
Why?
|
Evidence-Based Practice | 1 | 2008 | 499 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2022 | 10377 | 0.050 |
Why?
|
Safety | 1 | 2008 | 1159 | 0.050 |
Why?
|
Genotype | 2 | 2021 | 13038 | 0.050 |
Why?
|
Pyridines | 1 | 2014 | 2889 | 0.050 |
Why?
|
Registries | 3 | 2024 | 8378 | 0.050 |
Why?
|
Lung | 1 | 2021 | 10087 | 0.050 |
Why?
|
Germany | 1 | 2024 | 882 | 0.050 |
Why?
|
Sex Characteristics | 2 | 2023 | 2661 | 0.050 |
Why?
|
Tomography, X-Ray Computed | 4 | 2024 | 20766 | 0.050 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2013 | 2171 | 0.050 |
Why?
|
United States | 7 | 2024 | 73144 | 0.050 |
Why?
|
Immunohistochemistry | 1 | 2014 | 11117 | 0.040 |
Why?
|
Chelation Therapy | 1 | 2020 | 77 | 0.040 |
Why?
|
Surge Capacity | 1 | 2020 | 49 | 0.040 |
Why?
|
Stroke | 1 | 2022 | 9742 | 0.040 |
Why?
|
Censuses | 1 | 2021 | 198 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2019 | 39405 | 0.040 |
Why?
|
Cause of Death | 2 | 2021 | 3728 | 0.040 |
Why?
|
Skin Diseases | 1 | 2008 | 1084 | 0.040 |
Why?
|
Catheterization, Central Venous | 1 | 2005 | 536 | 0.040 |
Why?
|
Algorithms | 1 | 2020 | 14154 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2021 | 18047 | 0.040 |
Why?
|
Organizations, Nonprofit | 1 | 2020 | 105 | 0.040 |
Why?
|
Respiration, Artificial | 2 | 2021 | 2721 | 0.040 |
Why?
|
Platelet Glycoprotein GPIb-IX Complex | 1 | 2020 | 144 | 0.040 |
Why?
|
Mitral Valve | 1 | 2008 | 1474 | 0.040 |
Why?
|
Azithromycin | 1 | 2020 | 200 | 0.040 |
Why?
|
Prospective Studies | 4 | 2020 | 54921 | 0.040 |
Why?
|
Unconsciousness | 1 | 2020 | 251 | 0.040 |
Why?
|
Sex Factors | 2 | 2024 | 10656 | 0.040 |
Why?
|
Iodine | 1 | 2021 | 286 | 0.040 |
Why?
|
Pulmonary Circulation | 1 | 2021 | 744 | 0.040 |
Why?
|
Patient Care Management | 1 | 2021 | 304 | 0.040 |
Why?
|
Equipment Failure Analysis | 1 | 2020 | 848 | 0.040 |
Why?
|
Comparative Effectiveness Research | 1 | 2023 | 712 | 0.040 |
Why?
|
Age Factors | 1 | 2014 | 18472 | 0.040 |
Why?
|
Blood Coagulation Tests | 1 | 2019 | 270 | 0.040 |
Why?
|
Mortality | 2 | 2021 | 2917 | 0.040 |
Why?
|
Ferritins | 1 | 2020 | 601 | 0.040 |
Why?
|
Bone Marrow Examination | 1 | 2017 | 154 | 0.040 |
Why?
|
Europe | 1 | 2024 | 3439 | 0.040 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2008 | 1568 | 0.040 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2017 | 187 | 0.030 |
Why?
|
North America | 1 | 2020 | 1290 | 0.030 |
Why?
|
Group Processes | 1 | 2018 | 228 | 0.030 |
Why?
|
Ethanol | 1 | 2023 | 1333 | 0.030 |
Why?
|
Length of Stay | 2 | 2021 | 6516 | 0.030 |
Why?
|
Anemia, Hemolytic | 1 | 2017 | 164 | 0.030 |
Why?
|
Academic Medical Centers | 2 | 2017 | 2783 | 0.030 |
Why?
|
Cerebral Veins | 1 | 2017 | 158 | 0.030 |
Why?
|
Angiography | 1 | 2022 | 1597 | 0.030 |
Why?
|
Hemostatics | 1 | 2019 | 246 | 0.030 |
Why?
|
Hydroxychloroquine | 1 | 2020 | 426 | 0.030 |
Why?
|
Hospital Bed Capacity | 1 | 2017 | 206 | 0.030 |
Why?
|
Embolectomy | 1 | 2016 | 130 | 0.030 |
Why?
|
Prognosis | 3 | 2023 | 30020 | 0.030 |
Why?
|
Severity of Illness Index | 3 | 2021 | 15939 | 0.030 |
Why?
|
Catheterization, Swan-Ganz | 1 | 2016 | 86 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2023 | 2353 | 0.030 |
Why?
|
Incidental Findings | 1 | 2020 | 697 | 0.030 |
Why?
|
von Willebrand Factor | 1 | 2019 | 680 | 0.030 |
Why?
|
Comorbidity | 2 | 2020 | 10588 | 0.030 |
Why?
|
Radiography, Abdominal | 1 | 2017 | 541 | 0.030 |
Why?
|
Intracranial Hemorrhages | 1 | 2020 | 811 | 0.030 |
Why?
|
Education, Medical, Continuing | 1 | 2020 | 828 | 0.030 |
Why?
|
Medicare | 2 | 2023 | 6881 | 0.030 |
Why?
|
Survivors | 1 | 2024 | 2382 | 0.030 |
Why?
|
Disease Management | 1 | 2005 | 2536 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2022 | 1088 | 0.030 |
Why?
|
Pulmonary Medicine | 1 | 2016 | 223 | 0.030 |
Why?
|
Physician's Role | 1 | 2020 | 926 | 0.030 |
Why?
|
Models, Organizational | 1 | 2016 | 548 | 0.030 |
Why?
|
Deoxycytidine | 1 | 2018 | 887 | 0.030 |
Why?
|
Neural Pathways | 1 | 2024 | 3121 | 0.030 |
Why?
|
Databases, Factual | 2 | 2020 | 8072 | 0.030 |
Why?
|
Survival Analysis | 2 | 2018 | 10117 | 0.030 |
Why?
|
Drug Approval | 1 | 2020 | 818 | 0.030 |
Why?
|
Hematology | 1 | 2016 | 244 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2023 | 3520 | 0.030 |
Why?
|
Postoperative Hemorrhage | 1 | 2016 | 418 | 0.020 |
Why?
|
Splenectomy | 1 | 2013 | 392 | 0.020 |
Why?
|
Spleen | 1 | 2017 | 2295 | 0.020 |
Why?
|
Drug Costs | 1 | 2020 | 1196 | 0.020 |
Why?
|
Hospitals, General | 1 | 2016 | 807 | 0.020 |
Why?
|
United States Food and Drug Administration | 1 | 2020 | 1672 | 0.020 |
Why?
|
Abdominal Pain | 1 | 2017 | 1070 | 0.020 |
Why?
|
Critical Care | 1 | 2024 | 2716 | 0.020 |
Why?
|
Cell-Derived Microparticles | 1 | 2012 | 161 | 0.020 |
Why?
|
Autoantibodies | 1 | 2020 | 2126 | 0.020 |
Why?
|
Health Care Costs | 1 | 2024 | 3267 | 0.020 |
Why?
|
Interdisciplinary Communication | 1 | 2016 | 937 | 0.020 |
Why?
|
Vision Disorders | 1 | 2017 | 1093 | 0.020 |
Why?
|
Pregnancy | 2 | 2023 | 30198 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 1765 | 0.020 |
Why?
|
Thoracic Surgery | 1 | 2016 | 727 | 0.020 |
Why?
|
Medicine | 1 | 2017 | 948 | 0.020 |
Why?
|
Mutation | 3 | 2021 | 30230 | 0.020 |
Why?
|
Boston | 1 | 2021 | 9371 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2020 | 10776 | 0.020 |
Why?
|
Animals | 1 | 2020 | 169322 | 0.020 |
Why?
|
Time Factors | 2 | 2020 | 40267 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2020 | 3064 | 0.020 |
Why?
|
Contrast Media | 1 | 2021 | 5337 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2024 | 6670 | 0.020 |
Why?
|
Syndrome | 1 | 2013 | 3275 | 0.020 |
Why?
|
Exercise | 1 | 2024 | 5947 | 0.020 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2011 | 620 | 0.020 |
Why?
|
Survival Rate | 1 | 2021 | 12870 | 0.020 |
Why?
|
Fatigue | 1 | 2013 | 1555 | 0.020 |
Why?
|
Genetic Variation | 1 | 2021 | 6606 | 0.020 |
Why?
|
Physicians | 1 | 2024 | 4614 | 0.020 |
Why?
|
Diagnostic Tests, Routine | 1 | 2011 | 790 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2023 | 22292 | 0.020 |
Why?
|
Cardiology | 1 | 2016 | 1701 | 0.010 |
Why?
|
Child | 2 | 2024 | 80894 | 0.010 |
Why?
|
Odds Ratio | 1 | 2016 | 9681 | 0.010 |
Why?
|
Necrosis | 1 | 2008 | 1619 | 0.010 |
Why?
|
Prevalence | 1 | 2021 | 15868 | 0.010 |
Why?
|
Glucocorticoids | 1 | 2013 | 2168 | 0.010 |
Why?
|
Bone Marrow | 1 | 2013 | 2929 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2016 | 12092 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2018 | 11254 | 0.010 |
Why?
|
Brain | 2 | 2020 | 27452 | 0.010 |
Why?
|
Radiology | 1 | 2016 | 2117 | 0.010 |
Why?
|
Guidelines as Topic | 1 | 2008 | 1397 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2011 | 6541 | 0.010 |
Why?
|
Inflammation | 1 | 2020 | 10863 | 0.010 |
Why?
|
Young Adult | 2 | 2021 | 60048 | 0.010 |
Why?
|
Molecular Targeted Therapy | 1 | 2011 | 2830 | 0.010 |
Why?
|
Quality Assurance, Health Care | 1 | 2008 | 2180 | 0.010 |
Why?
|
Colonic Neoplasms | 1 | 2008 | 2542 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2011 | 8051 | 0.010 |
Why?
|
Societies, Medical | 1 | 2008 | 3960 | 0.010 |
Why?
|
Decision Making | 1 | 2008 | 3953 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2020 | 36849 | 0.010 |
Why?
|
Research Design | 1 | 2008 | 6209 | 0.010 |
Why?
|